Scripps Research appoints global health advocate Lillian Lou to Board of Directors
June 30, 2021
LA JOLLA, CA—Lillian (Lily) Lou, PhD, who led a successful career in biotechnology before transitioning to global health issues, has joined Scripps Research’s Board of Directors.

Lillian Lou, PhD
Lou is President and Program Director of The John C. Martin Foundation, a private nonprofit organization working to bring improved healthcare to socially and economically disadvantaged populations. The Foundation was founded by her late life partner, John C. Martin, who had also served as a Scripps Research board member.
“Lily brings added strength to our Board of Directors, with experience spanning many key areas of science and global health,” says Scripps Research President and CEO Peter Schultz, PhD. “As a team, Lily and John were a humanitarian force that changed lives all over the world. As Lily continues this important work, we are privileged she will be sharing her voice and ideas to help us carry out our mission as a globally minded biomedical institute.”
Lou has run The John C. Martin Foundation since its inception and formation in 2014. The Foundation was established with the goal to facilitate sustainable improvement of health care with a focus on the advancement of control and prevention of endemic illnesses among underserved populations.
Prior to the Foundation, Lou had over 20 years of work experience in the pharmaceutical industry. She directed discovery biology research and clinical studies, and managed regulatory and medical affairs in several pharma and biotech companies focusing on disease areas including viral hepatitis and inflammatory diseases like lupus. Lily was also responsible for leading the medical science activities in HIV/AIDS and viral hepatitis especially in resource-challenged countries in Africa, South-Southeast Asia, Eastern Europe and Latin America.
Lou earned her PhD in biochemistry from the University of California, Los Angeles, followed by a postdoctoral fellowship at Stanford University.
Calibr-Skaggs advances CLF065, a regenerative GLP-2 therapy, into two Phase 2 IBD studies
CLF065, a long-acting, once-weekly GLP-2 receptor agonist, advances in two inflammatory bowel disease indications. The studies aim to bring a regenerative treatment option to patients living with IBD, who currently have few therapies that repair the damaged intestinal lining at the root of their disease.
Advancing the vision: An experiment in rethinking the nonprofit biomedical research model
In his Front Row lecture, President and CEO Pete Schultz highlighted the progress Scripps Research has made in pioneering a new model for non-profit biomedical research. He described how integrating basic science and translational research under one roof is accelerating next-generation medicines—from new immunotherapies for cancer and innovative medicines for infectious disease to regenerative treatments for heart, lung and intestinal tissues. At a time of uncertainty in federal science funding, this model isn't only advancing human health but also helping to generate sustainable support for innovative scientific research and for training the next generation of scientific leaders.
Viome and Scripps Research partner to develop first at-home RNA screening test to prevent colon cancer before it strikes
First-of-its-kind 1,000-patient clinical study will use RNA-based stool and saliva tests to detect colon polyps — early warning signs of colorectal cancer — before they become cancerous.Study aims to enhance colorectal cancer prevention by identifying polyp molecular signals, offering improved sensitivity over at-home DNA tests, which have limited ability to detect precancerous lesions.
Enzyme engineering opens door to novel therapies for Parkinson’s, cancers and other hard-to-target protein diseases
Researchers reprogrammed a botulinum toxin protease to selectively break down disease-causing proteins in human cells, providing proof of concept for developing new therapies for a wide range of illnesses.